Peramivir - BioCryst Pharmaceuticals

Drug Profile

Peramivir - BioCryst Pharmaceuticals

Alternative Names: ALPIVAB; BCX-1812; JNJ-2; PeramiFlu; Rapiacta; Rapivab; RWJ-270201

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCryst Pharmaceuticals; University of Alabama
  • Developer BioCryst Pharmaceuticals; Green Cross; Shionogi
  • Class Acetamides; Antivirals; Carboxylic acids; Cyclopentanes; Guanidines; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype; Influenza virus infections

Most Recent Events

  • 07 Nov 2017 Shionogi plans a clinical trial in Influenza virus infections (A and B) in Japan (UMIN000030118)
  • 04 Oct 2017 Interim efficacy and adverse data in Influenza virus infections released by BioCryst Pharmaceuticals (NCT02369159)
  • 21 Sep 2017 Registered for Influenza virus infections (In adolescents, In children) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top